Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
InChiKey: YHPWOYBWUWSJDW-UQKRIMTDSA-N
CAS Number: 23239-51-2
CAS Number: 1198117-23-5
Currently Novartis is conducting a clinical trial with this drug on obsessive compulsive disorder
Kadoshima T
CAL-130 Hydrochloride - CAS# 1431697-78-7 60153 InChiKey: YHPWOYBWUWSJDW-UQKRIMTDSA-NCAL 130 is a potent and selective PI3K gamma and delta inhibitor with potential anticancer activity. Constitutive phosphoinositide 3 kinase (PI3K) Akt activation is common in T cell acute lymphoblastic leukemia (T ALL). Although four distinct class I PI3K isoforms (, , , ) could participate in T ALL pathogenesis, none has been implicated in this process. In the absence of PTEN phosphatase tumor suppressor function, PI3K or PI3K alone can support
US$ 104.50
US$ 99.00
US$ 15.99
US$ 15.99
US$ 164.50
US$ 24.00
US$ 40.00
US$ 184.50
US$ 15.99
US$ 22.00
US$ 98.00